Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vor Biopharma

< Previous 1 2 Next >
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces $175 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces $55.6 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.